Axsome Therapeutics (AXSM) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Axsome Therapeutics Revenue Highlights


Latest Revenue (Y)

$270.60M

Latest Revenue (Q)

$87.17M

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Axsome Therapeutics Revenue by Period


Axsome Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$270.60M440.80%
2022-12-31$50.04M100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31--

Axsome Therapeutics generated $270.60M in revenue during NA 2023, up 440.80% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Axsome Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30$87.17M16.22%
2024-03-31$75.00M4.85%
2023-12-31$71.53M23.77%
2023-09-30$57.79M23.76%
2023-06-30$46.70M-50.62%
2023-03-31$94.58M288.06%
2022-12-31$24.37M44.67%
2022-09-30$16.85M91.00%
2022-06-30$8.82M100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30--

Axsome Therapeutics generated $87.17M in revenue during Q2 2024, up 16.22% compared to the previous quarter, and up 92.17% compared to the same period a year ago.

Axsome Therapeutics Revenue Breakdown


Axsome Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23
Royalty$2.40M
License$65.73M
Product$202.46M

Axsome Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (74.82%), License (24.29%), and Royalty (0.89%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Jun 23Mar 23
Product$103.74M$74.10M$70.75M$57.13M$46.02M$28.57M
Royalty$1.03M$903.00K$783.00K$667.00K$683.00K$272.00K
License---$65.73M$65.73M-

Axsome Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (99.02%), and Royalty (0.98%).

Axsome Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22
UNITED STATES$197.22M-
Non-US$65.73M$900.00K

Axsome Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (75.00%), and Non-US (25.00%).

Quarterly Revenue by Country

CountrySep 24Mar 24Dec 23Sep 23Jun 23Mar 23
Non-US$1.03M$903.00K-$65.73M$600.00K$1.70M
UNITED STATES$102.81M$73.27M$141.44M$55.78M--

Axsome Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (99.01%), and Non-US (0.99%).

Axsome Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
INCYIncyte$3.70B$962.99M
SRPTSarepta Therapeutics$1.24B$362.93M
ACADACADIA Pharmaceuticals$726.44M$250.40M
AMLXAmylyx Pharmaceuticals$380.79M$416.00K
AXSMAxsome Therapeutics$270.60M$87.17M
BPMCBlueprint Medicines$249.38M$128.18M
TGTXTG Therapeutics$233.66M$83.88M
MCRBSeres Therapeutics$126.33M-
VKTXViking Therapeutics--
PDSBPDS Bio--
DAWNDay One Biopharmaceuticals-$20.07M
MDGLMadrigal Pharmaceuticals-$62.17M
TERNTerns Pharmaceuticals--
AKROAkero Therapeutics--
HEPAHepion Pharmaceuticals--

AXSM Revenue FAQ


What is Axsome Therapeutics’s yearly revenue?

Axsome Therapeutics's yearly revenue for 2023 was $270.6M, representing an increase of 440.80% compared to 2022. The company's yearly revenue for 2022 was $50.04M, representing an increase of 100.00% compared to 2021. AXSM's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.

What is Axsome Therapeutics’s quarterly revenue?

Axsome Therapeutics's quarterly revenue for Q2 2024 was $87.17M, a 16.22% increase from the previous quarter (Q1 2024), and a 86.65% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $75M, a 4.85% increase from the previous quarter (Q4 2023), and a -20.70% decrease year-over-year (Q1 2023). AXSM's quarterly revenue for Q4 2023 was $71.53M, a 23.77% increase from the previous quarter (Q3 2023), and a 193.50% increase year-over-year (Q4 2022).

What is Axsome Therapeutics’s revenue growth rate?

Axsome Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.

What are Axsome Therapeutics’s revenue streams?

Axsome Therapeutics's revenue streams in c 23 are Royalty, License, and Product. Royalty generated $2.4M in revenue, accounting 0.89% of the company's total revenue License generated $65.74M in revenue, accounting 24.29% of the company's total revenue Product generated $202.46M in revenue, accounting 74.82% of the company's total revenue

What is Axsome Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Axsome Therapeutics was Product. This segment made a revenue of $202.46M, representing 74.82% of the company's total revenue.